Monitor Response to Treatment in Neuroblastoma Using 3&Apos;-Deoxy-3&Apos;-Fluorothymidine- Positron Emission Tomography (FLT-PET)

Inclusion Criteria: * All patients with neuroblastoma or suspected neuroblastoma seen at Children's Hospital of Michigan (CHM). Patients need to be 2 years or older to be eligible for the initial study * Patients must be 1 day to 21 years old, there is no gender limit. * Diagnosis: All patients with neuroblastoma or suspected neuroblastoma, including newly diagnosed and relapsed patients, are eligible for Objective 1. To be eligible for Objective 2, patients must have a diagnosis of neuroblastoma verified by histology or demonstration of clumps of tumor cells in bone marrow with elevated urinary catecholamine metabolites, and have measurable disease after the initial surgery * Female adolescent patients must have a negative pregnancy test within 14 days of first imaging and should not be pregnant * Patients must be able to lie still for the tests, or have no contraindication for sedation * Patients or their legal guardian must sign an informed consent indicating that they are aware of the investigational nature of this study * A total number of 40-50 patients will be included in the study Exclusion Criteria: * Patients who do not have a histology diagnosis of neuroblastoma are not eligible for the study * Patients whose definite diagnosis after surgery is not consistent with the diagnosis of neuroblastoma will be included in the Objective 1 but excluded for Objective 2.